Home   >  
Microbiology/Virology
  >  
CMV
  >   Valganciclovir hydrochloride
Valganciclovir hydrochloride Chemical Structure

Valganciclovir hydrochloride

Data Sheet For research use only. Not for human use.
Cat. No. :BCP08146CAS No. :175865-59-5Purity:98%
 Tel: 0086-17754423994   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 175865-59-5 Cat. No. BCP08146
Name Valganciclovir hydrochloride
Synonyms
SMILES
Chemical Name
Formula C14H23ClN6O5 M. Wt 390.83
Purity 98% Storage Store at 4-8°C
Description in vitro: In cell culture model systems using Caco-2 cells for PEPT1 and SKPT cells for PEPT2, valganciclovir inhibited glycylsarcosine transport mediated by PEPT1 and PEPT2 with K(i) values (inhibition constant) of 1.68+/-0.30 and 0.043+/- 0.005 mM, respectively. The inhibition by valganciclovir was competitive in both cases . in vivo: 37 patients were enrolled; 19 patients received treatment with VGV and 18 patients received treatment with GCV. The VGV was not inferior in efficacy to GCV as pre-emptive therapy, with rates of viral clearance at 28 days of 89.5% and 83%, respectively (P-value for non-inferiority = 0.030). Toxicities were similar between the 2 arms. No patients developed CMV disease [2]. Patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily orvalganciclovir 450 mg orally twice daily. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004) .
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Valganciclovir hydrochloride supplier,Valganciclovir hydrochloride purchase,Valganciclovir hydrochloride manufacturer,Valganciclovir hydrochloride distributor,Valganciclovir hydrochloride cost,Valganciclovir hydrochloride buy,Valganciclovir hydrochloride for sale

0086-13720134139